AI
Tuesday, December 06, 2016 5:42:16 PM
Mem.Sloan’s Jedd.Wolchok Video/July2014: “Immunotherapy for Metastatic Melanoma, PD-1 Clinical Trials”… Dr. Wolchok (1:42), “We will not rest until every patient can have a durable response.” http://cyberspaceandtime.com/kvWeW8Zt0sU.video (1:49)
TOMORROW:
12-7-16/WED 10am: JEDD D. WOLCHOK, MD/PhD(Mem. Sloan Kettering)
Lecture: ”Combination Checkpoint Blockade" (free to public)
Location: The Wistar Institute, Philadelphia (Jedd D. Wolchock: Chief of Melanoma & Immunotherapeutics Service, MSKCC)
https://www.wistar.org/events/2016/12/combination-checkpoint-blockade
...We don’t know if Dr. Wolchok will mention Peregrine/Bavi in his talk (North40000/Eb0783/Wook will let us know!), but RECALL that on 11-14-16, Dr. Wolchok’s MSKCC Lab Team, jointly with PPHM Scientists, presented a poster at SITC’16 on Triple Combo Rad+Bavi+aPD1 vs. Melanoma:
...11-14-16/SITC’16: Dr. Jedd Wolchok states, “Based on these study results, we believe that the targeting of PS is having meaningful activity within the tumor microenvironment in the B16 melanoma model. It appears that this activity creates a more immune active environment in which other treatments, including radiation, are able to have a greater anti-tumor impact.”
#199/SITC’16/11-11-16(MSK+PPHM): Phosphatidylserine Targeting Antibody in Combination with Checkpoint Blockade & Tumor Radiation Therapy Promotes Anti-Cancer Activity in Mouse Melanoma” See: http://tinyurl.com/js3fca4
5-29-15: Peregrine & Sloan Kettering Enter Collab. to “Investigate Novel PS-Targeting Immunotherapy Combos” http://tinyurl.com/o3k9ux8
= = = = = = = = = = = = = = = =KNOWN DECEMBER:
Dec7/WED: WCLC’16 - IASLC’s 17th World Conf. on Lung Cancer, Vienna, Austria http://tinyurl.com/z8cq8vx
…2:30-3:45pm UTSW’s Dr. David Gerber to present addl. Biomarker data from Ph3.SUNRISE Trial: “A Pre-Treatment Serum Test Based on Complement & IL-10 Pathways Identifies Patients Benefiting from the Addition of Bavituximab to Docetaxel”
Dec7/WED 10am: MSKCC’s Dr. Jedd Wolchok lecture at Wistar on “Combination Checkpoint Blockade"
Dec8/THU: 39th San Antonio Breast Cancer Symposium” http://tinyurl.com/zb5sopc
...Dr. Bruce Freimark(Dir.Res/Preclin.Oncology) poster: “PS-Targeting Enhances Anti-LAG3 in Murine Breast Cancer Tumors”
Dec12/MON/AfterMkt: FY'17Q2 (qe 10-31-16) Financials & Conf. Call - http://ir.peregrineinc.com/events.cfm
Dec11-15/Avid/Booth#209: IBC's Antibody Eng. & Therapeutics 2016”, SanDiego http://www.ibclifesciences.com/AntibodyEng/overview.xml
CONCLUSION SECTION FROM THE JOINT MSKCC/PPHM SITC’16 POSTER:
11-14-16/SITC'16: Dr. Taha Merghoub (Co-Dir., Ludwig Collaborative Lab at MSK): "We have noted that the combination of PS-targeting treatment and radiation, as well as triple combination of PS-targeting treatment, radiation and anti-PD-1, resulted in clear advantages in anti-tumor activity in the mouse B16 melanoma model. We believe that these findings suggest the potential benefit of combining these agents to improve the outcomes of patients with cancer. With this in mind, we think this research may play an important role in designing future clinical trials of PS-targeting agents in melanoma and other cancers."
http://tinyurl.com/js3fca4
= = = = = = =
Oct9-11 2017: “EACR Conf. - Defense is the Best Attack: Immuno-Oncology Breakthroughs”, Barcelona
https://www.eacr.org/meeting/defence-is-the-best-attack-immuno-oncology-breakthroughs
EACR = Eur. Association for Cancer Research https://www.eacr.org
Keynote Speaker: Dr. Jedd Wolchok, MSKCC
TOMORROW:
12-7-16/WED 10am: JEDD D. WOLCHOK, MD/PhD(Mem. Sloan Kettering)
Lecture: ”Combination Checkpoint Blockade" (free to public)
Location: The Wistar Institute, Philadelphia (Jedd D. Wolchock: Chief of Melanoma & Immunotherapeutics Service, MSKCC)
https://www.wistar.org/events/2016/12/combination-checkpoint-blockade
...We don’t know if Dr. Wolchok will mention Peregrine/Bavi in his talk (North40000/Eb0783/Wook will let us know!), but RECALL that on 11-14-16, Dr. Wolchok’s MSKCC Lab Team, jointly with PPHM Scientists, presented a poster at SITC’16 on Triple Combo Rad+Bavi+aPD1 vs. Melanoma:
...11-14-16/SITC’16: Dr. Jedd Wolchok states, “Based on these study results, we believe that the targeting of PS is having meaningful activity within the tumor microenvironment in the B16 melanoma model. It appears that this activity creates a more immune active environment in which other treatments, including radiation, are able to have a greater anti-tumor impact.”
#199/SITC’16/11-11-16(MSK+PPHM): Phosphatidylserine Targeting Antibody in Combination with Checkpoint Blockade & Tumor Radiation Therapy Promotes Anti-Cancer Activity in Mouse Melanoma” See: http://tinyurl.com/js3fca4
5-29-15: Peregrine & Sloan Kettering Enter Collab. to “Investigate Novel PS-Targeting Immunotherapy Combos” http://tinyurl.com/o3k9ux8
= = = = = = = = = = = = = = = =KNOWN DECEMBER:
Dec7/WED: WCLC’16 - IASLC’s 17th World Conf. on Lung Cancer, Vienna, Austria http://tinyurl.com/z8cq8vx
…2:30-3:45pm UTSW’s Dr. David Gerber to present addl. Biomarker data from Ph3.SUNRISE Trial: “A Pre-Treatment Serum Test Based on Complement & IL-10 Pathways Identifies Patients Benefiting from the Addition of Bavituximab to Docetaxel”
Dec7/WED 10am: MSKCC’s Dr. Jedd Wolchok lecture at Wistar on “Combination Checkpoint Blockade"
Dec8/THU: 39th San Antonio Breast Cancer Symposium” http://tinyurl.com/zb5sopc
...Dr. Bruce Freimark(Dir.Res/Preclin.Oncology) poster: “PS-Targeting Enhances Anti-LAG3 in Murine Breast Cancer Tumors”
Dec12/MON/AfterMkt: FY'17Q2 (qe 10-31-16) Financials & Conf. Call - http://ir.peregrineinc.com/events.cfm
Dec11-15/Avid/Booth#209: IBC's Antibody Eng. & Therapeutics 2016”, SanDiego http://www.ibclifesciences.com/AntibodyEng/overview.xml
CONCLUSION SECTION FROM THE JOINT MSKCC/PPHM SITC’16 POSTER:
11-14-16/SITC'16: Dr. Taha Merghoub (Co-Dir., Ludwig Collaborative Lab at MSK): "We have noted that the combination of PS-targeting treatment and radiation, as well as triple combination of PS-targeting treatment, radiation and anti-PD-1, resulted in clear advantages in anti-tumor activity in the mouse B16 melanoma model. We believe that these findings suggest the potential benefit of combining these agents to improve the outcomes of patients with cancer. With this in mind, we think this research may play an important role in designing future clinical trials of PS-targeting agents in melanoma and other cancers."
http://tinyurl.com/js3fca4
= = = = = = =
Oct9-11 2017: “EACR Conf. - Defense is the Best Attack: Immuno-Oncology Breakthroughs”, Barcelona
https://www.eacr.org/meeting/defence-is-the-best-attack-immuno-oncology-breakthroughs
EACR = Eur. Association for Cancer Research https://www.eacr.org
Keynote Speaker: Dr. Jedd Wolchok, MSKCC
